Search This Blog

Thursday, January 23, 2020

China’s latest virus outbreak exposes perils of exotic wildlife trade

A new coronavirus spreading from the city of Wuhan has put a spotlight on China’s poorly regulated wild animal trade – driven by relentless demand for exotic delicacies and ingredients for traditional medicine.
China’s markets, where wild and often poached animals are packed together, have been described as a breeding ground for disease and an incubator for a multitude of viruses to evolve and jump the species barrier to humans.
More than 500 people have been infected by the new flu-like virus that authorities say emerged from illegally traded wildlife in a seafood market in the central Chinese city, with the death toll at 17 and expected to rise.
“The origin of the new coronavirus is the wildlife sold illegally in a Wuhan seafood market,” Gao Fu, director of China Center for Disease Control and Prevention, told a briefing.
Preliminary research suggested that in the most recent stage of its evolution, the Wuhan virus was passed on to humans from snakes. But Chinese government medical adviser Zhong Nanshan has also identified badgers and rats as possible sources.

Conservationists and health experts have long denounced the trade in wildlife for its impact on biodiversity and the potential for spreading disease in markets.
“The animal welfare part of this is obvious, but much more hidden is this stashing and mixing of all these species together in a very small area, with secretions and urine mixed up together,” said Christian Walzer, executive director of the New York-based Wildlife Conservation Society.
China’s wet markets have already been blamed for outbreaks of other infectious diseases in China and southeast Asia, including the virus responsible for Severe Acute Respiratory Syndrome (SARS), which killed nearly 800 people worldwide in 2003.
“The other thing you have to consider is that these animals are massively stressed in these cages so their immune systems fail very quickly,” said Walzer.
“It is a perfect system. You couldn’t do it any better if you tried,” Walzer said of the markets’ propensity to generate viruses.

MARKET FORCES

Photographs taken at the Wuhan market before it was closed at the end of last year show cages packed with snakes, porcupines and foxes. Media said about 50 types of wild animal were on sale at the market, including endangered pangolins.
According to a report by the China Business Journal, a state-owned paper that interviewed the sister of a vendor infected by the virus, snakes, ducks and wild rabbits were popular at the market.
Since the outbreak began, authorities in Wuhan and elsewhere have shut down markets, zoos and forest parks, suspended trade in live poultry and the trade and transport of wild animals, though residents in some areas said the measures appeared to be largely symbolic.
The southeastern province of Guangdong, where a wide variety of animals are sold, has long been regarded as a prime source of new diseases.
Scientists believe SARS was caused by cross-species transmission in the province – with the blame initially falling on masked palm civets, which are considered a delicacy.
Authorities slaughtered thousands of the animals although bats were later believed to have been the source of SARS.
After SARS, China tried to improve the way the animal trade is regulated. At the same time, authorities have tried to curb the poaching of exotic species and has a long list of officially protected wildlife.
But efforts to protect animals often lose out to generations of tradition.
Environmentalists have long campaigned for new laws to restrict the use of wild animals in Chinese medicine and to develop synthetic alternatives.
But many animal products are still easily available.
Snakes, peacocks and even crocodiles are on sale via Taobao, a Chinese e-commerce website run by Alibaba.

Reuters contacted an Inner Mongolia resident named Gong Jian who sells snake, camel, crocodile and deer meat via WeChat.
Given booming business, he said he was aiming to expand his online marketing.
“Customers really like the crocodile – they stew it,” he said.
https://www.reuters.com/article/us-china-health-wildlife/chinas-latest-virus-outbreak-exposes-perils-of-exotic-wildlife-trade-idUSKBN1ZM0PE

16 people under observation after contact with U.S. coronavirus patient

At least 16 people had close contact with a Washington state man diagnosed as the first U.S. case of the coronavirus and are being monitored for the illness that has killed 17 people in China and sickened hundreds more, local officials said.
The patient, a 30-year-old man, is doing well and may be released from Providence Regional Medical Center in Everett, Washington in the near future, the hospital’s chief medical officer Jay Cook told a press conference.
None of the people who were in close contact with the patient have displayed symptoms of the flu-like illness, said John Wiesman, secretary of health for Washington State.
“The risk to the general public remains low,” said Chris Spitters, health officer for the Snohomish Health District.
The man fell ill over the weekend after traveling to Wuhan, China, his hometown, in November and December and was diagnosed with the coronavirus on Monday.
The virus, which causes respiratory symptoms, has been linked to a seafood market in Wuhan, the largest city in central China.

“I would expect at some point we’re going to have more cases in the U.S.,” said Wiesman.
Passengers aboard the man’s flight from China are being contacted by the U.S. Centers for Disease Control and state health authorities, said CDC Medical Officer Satish Pillai.
The CDC has raised its travel alert for Wuhan to a level 2, calling for enhanced precautions. All travelers from Wuhan are being directed to five U.S. airports – in Los Angeles, New York, Chicago, Atlanta and San Francisco – for screening.
The CDC is developing a test for the virus and hopes to start distributing it to state health departments, Pillai said.
Wiesman said people had to be within six feet of a person with the virus for a prolonged period to be deemed to have been in close contact.
People develop the virus after droplets from an infected person’s sneeze or cough fall on them, he said.

The 16 individuals under observation in Washington are not being asked to go into isolation unless they develop coronavirus symptoms, Wiesman said.
“We don’t believe you are infectious until you have symptoms,” he said, giving no further details on the locations of individuals who had been in close contact with the infected man.
https://www.reuters.com/article/us-china-health-usa/16-people-under-observation-after-contact-with-u-s-coronavirus-patient-idUSKBN1ZM0S3

Avinger up on start of new artery treatment study

Enrollment is underway in a post-marketing trial, IMAGE-BTK, evaluating Avinger’s (NASDAQ:AVGR) Pantheris SV image-guided atherectomy system for the treatment of peripheral artery lesions below-the-knee (BTK).
The primary endpoint of the 60-subject study is the reduction in residual stenosis in target lesions on a standalone basis.
The company launched the device in the U.S. in Q3 2019.

Evoke Pharma up on Gimoti deal in U.S

Thinly traded nano cap Evoke Pharma (NASDAQ:EVOK) perks up 10% premarket on modestly higher volume on the heels of its agreement with life sciences commercial services provider Eversana for the commercialization and distribution of Gimoti (metoclopramide) nasal spray in the U.S.
Under the terms of the deal, EVOK will reimburse Eversana for certain costs and a percentage of profits (mid-to-high teens) after Gimoti sales surpass a certain level. Eversana has also agreed to provide a credit revolver to EVOK up to $5M.
Its marketing application for adult women with acute or recurrent diabetic gastroparesis is currently under FDA review with an action date of June 19.
EVOK and Novos Growth Partners have mutually agreed to terminate their commercialization agreement inked a year ago.
https://seekingalpha.com/news/3533947-evoke-pharma-up-10-premarket-on-gimoti-deal-in-u-s

Moderna nabs funding to make vaccine against China coronavirus

The Coalition for Epidemic Preparedness Innovations (CEPI), a public-private coalition aimed at accelerating the development of vaccines, has agreed to fund the manufacture of Moderna’s (MRNA -1.8%) mRNA vaccine against the coronavirus causing the outbreak in China, named 2019-nCoV.
NIH’s National Institute of Allergy and Infectious Diseases (NIAID), Moderna’s collaborator on the design of the vaccine, will conduct IND-enabling studies as well as a Phase 1 clinical trial.
https://seekingalpha.com/news/3533957-moderna-nabs-funding-to-make-vaccine-against-china-coronavirus

Altimmune up on encouraging ALT-702 data

Thinly traded nano cap Altimmune (NASDAQ:ALT) is up 6% premarket on robust volume in reaction to preclinical data on ALT-702.
Three doses of ALT-702, injected into one tumor mass over five days in conjunction with an anti-CTLA4 antibody administered intraperitoneally (into the body cavity), were evaluated in a mouse model based on the CT26 colorectal carcinoma cell line.
Tumor regression was observed in both injected and non-injected lesions and overall survival was “markedly better” for the combo compared to either agent alone.
The company says ALT-702 is a targeted tumor immunostimulant, a dual TLR7/8 agonist conjugated to its depot-forming technology, designed to reverse local immunosuppression within the tumor microenvironment and stimulate systemic antitumor immune responses.
https://seekingalpha.com/news/3533898-altimmune-up-6-premarket-on-encouraging-altminus-702-data

Onconova regains rigosertib rights in China

Onconova Therapeutics (NASDAQ:ONTX) is up 17% premarket on robust volume in reaction to its announcement that it has regained the rights to rigosertib in Greater China subsequent to the termination of its license agreement with HanX Biopharmaceuticals after the latter failed to make required payments.
https://seekingalpha.com/news/3533936-onconova-regains-rigosertib-rights-in-china-shares-up-17-premarket